Literature DB >> 31324451

Modeling Hypertrophic Cardiomyopathy: Mechanistic Insights and Pharmacological Intervention.

Diogo Mosqueira1, James G W Smith2, Jamie R Bhagwan3, Chris Denning3.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a prevalent and complex cardiovascular disease where cardiac dysfunction often associates with mutations in sarcomeric genes. Various models based on tissue explants, isolated cardiomyocytes, skinned myofibrils, and purified actin/myosin preparations have uncovered disease hallmarks, enabling the development of putative therapeutics, with some reaching clinical trials. Newly developed human pluripotent stem cell (hPSC)-based models could be complementary by overcoming some of the inconsistencies of earlier systems, whilst challenging and/or clarifying previous findings. In this article we compare recent progress in unveiling multiple HCM mechanisms in different models, highlighting similarities and discrepancies. We explore how insight is facilitating the design of new HCM therapeutics, including those that regulate metabolism, contraction and heart rhythm, providing a future perspective for treatment of HCM.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  CRISPR/Cas9; HCM mechanisms; HCM treatment; disease modeling; genome editing; human pluripotent stem cells; hypertrophic cardiomyopathy

Mesh:

Substances:

Year:  2019        PMID: 31324451     DOI: 10.1016/j.molmed.2019.06.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  16 in total

1.  Transcriptomic Analysis of Cardiomyocyte Extracellular Vesicles in Hypertrophic Cardiomyopathy Reveals Differential snoRNA Cargo.

Authors:  Victoria James; Zubair A Nizamudeen; Daniel Lea; Tania Dottorini; Terri L Holmes; Benjamin B Johnson; Kenton P Arkill; Chris Denning; James G W Smith
Journal:  Stem Cells Dev       Date:  2021-12-15       Impact factor: 3.272

2.  Soluble ST2, Galectin-3 and clinical prognosis of patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy: a correlation analysis.

Authors:  Bangrong Song; Bo Yao; Haiming Dang; Ran Dong
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

Review 3.  Crosstalk between GSK-3β-actuated molecular cascades and myocardial physiology.

Authors:  Arun K Sharma; Saurabh Bhatia; Ahmed Al-Harrasi; Mukesh Nandave; Hanan Hagar
Journal:  Heart Fail Rev       Date:  2021-11       Impact factor: 4.214

4.  Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy.

Authors:  Maria Tafelmeier; Andrea Baessler; Stefan Wagner; Bernhard Unsoeld; Andrej Preveden; Fausto Barlocco; Alessia Tomberli; Dejana Popovic; Paul Brennan; Guy A MacGowan; Arsen Ristic; Lazar Velicki; Iacopo Olivotto; Djordje G Jakovljevic; Lars S Maier
Journal:  Clin Cardiol       Date:  2020-03-03       Impact factor: 2.882

5.  High-Throughput Phenotyping Toolkit for Characterizing Cellular Models of Hypertrophic Cardiomyopathy In Vitro.

Authors:  Diogo Mosqueira; Katarzyna Lis-Slimak; Chris Denning
Journal:  Methods Protoc       Date:  2019-10-26

6.  Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format.

Authors:  Ingra Mannhardt; Umber Saleem; Diogo Mosqueira; Malte F Loos; Bärbel M Ulmer; Marc D Lemoine; Camilla Larsson; Caroline Améen; Tessa de Korte; Maria L H Vlaming; Kate Harris; Peter Clements; Chris Denning; Arne Hansen; Thomas Eschenhagen
Journal:  Stem Cell Reports       Date:  2020-10-13       Impact factor: 7.765

7.  Transfection of hPSC-Cardiomyocytes Using Viafect™ Transfection Reagent.

Authors:  Sara E Bodbin; Chris Denning; Diogo Mosqueira
Journal:  Methods Protoc       Date:  2020-08-09

8.  Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation.

Authors:  Lorenzo R Sewanan; Jinkyu Park; Michael J Rynkiewicz; Alice W Racca; Nikolaos Papoutsidakis; Jonas Schwan; Daniel L Jacoby; Jeffrey R Moore; William Lehman; Yibing Qyang; Stuart G Campbell
Journal:  J Gen Physiol       Date:  2021-07-28       Impact factor: 4.086

9.  Mitochondrial DNA: Hotspot for Potential Gene Modifiers Regulating Hypertrophic Cardiomyopathy.

Authors:  Parisa K Kargaran; Jared M Evans; Sara E Bodbin; James G W Smith; Timothy J Nelson; Chris Denning; Diogo Mosqueira
Journal:  J Clin Med       Date:  2020-07-23       Impact factor: 4.964

10.  Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.

Authors:  Jamie R Bhagwan; Diogo Mosqueira; Karolina Chairez-Cantu; Ingra Mannhardt; Sara E Bodbin; Mine Bakar; James G W Smith; Chris Denning
Journal:  J Mol Cell Cardiol       Date:  2020-06-10       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.